Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • irate.pirate
    Junior Member
    • Feb 2025
    • 6

    Significant variation in FastQ File Sizes - Fragmentation Issue?

    Hi all, I’m pretty new to NGS and library prep. I just completed library prep and WES for a pilot of 12 FFPE DNA samples, and got back Fastq files that varied dramatically in size. I used NEB FFPE DNA prep kit and created normalized pooled libraries immediately after tape station results. However, my tumor samples were overrepresented pretty dramatically, with some samples having fastq files nearly 6 times larger. I’m pretty stuck as to why this happened, as the bioanalyzer curves looked pretty consistent across my samples and I used 11 PCR cycles for the NEB kit.

    Specifically, my PT6 and PT5 samples had HUGE fastq file sizes, and normalized those samples by spiking in a larger volume of those samples. Attached are my bioanalyzer curves, all of my "PT" samples had much larger fastq files (ranging from 8-17gb for each R1/R2 complement), compared to fastq file sizes of PM and N tissues being between 2.5-5gb. My analysis pipeline for these samples to get insert size and coverage is still running for the larger fastq files.

    What can explain why some of my fastq files are so large, even after normalizing the concentrations from bioanalyzer data just prior to pooling my samples? Is this due to an issue with fragmentation (large fragments on the non-tumor samples causing under sequencing), and if so how can this be mitigated in the future? If this is from daisy-chaining, would this cause unusually low or high sequencing ratio for those samples? Would appreciate any help!

Latest Articles

Collapse

  • SEQadmin2
    Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
    by SEQadmin2


    Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

    The systematic characterization of the human proteome has
    ...
    07-20-2026, 11:48 AM
  • SEQadmin2
    Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
    by SEQadmin2



    Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
    ...
    07-09-2026, 11:10 AM
  • SEQadmin2
    Cancer Drug Resistance: The Lingering Barrier to Rising Survival
    by SEQadmin2



    Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

    There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
    07-08-2026, 05:17 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, Today, 12:17 PM
0 responses
10 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, Yesterday, 11:41 AM
0 responses
11 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-20-2026, 11:10 AM
0 responses
23 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 07-13-2026, 10:26 AM
0 responses
37 views
0 reactions
Last Post SEQadmin2  
Working...